R.M. Ore
University of Kentucky
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by R.M. Ore.
Diagnostics | 2017
R.M. Ore; L.A. Baldwin; Dylan Woolum; Erika Elliott; Christiaan Wijers; Chieh-Yu Chen; R.W. Miller; Christopher P. DeSimone; Frederick R. Ueland; Richard J. Kryscio; John R. van Nagell; Edward J. Pavlik
To examine how frequently and confidently healthy women report symptoms during surveillance for ovarian cancer. A symptoms questionnaire was administered to 24,526 women over multiple visits accounting for 70,734 reports. A query of reported confidence was included as a confidence score (CS). Chi square, McNemars test, ANOVA and multivariate analyses were performed. 17,623 women completed the symptoms questionnaire more than one time and >9500 women completed it more than one four times for >43,000 serially completed questionnaires. Reporting ovarian cancer symptoms was ~245 higher than ovarian cancer incidence. The positive predictive value (0.073%) for identifying ovarian cancer based on symptoms alone would predict one malignancy for 1368 cases taken to surgery due to reported symptoms. Confidence on the first questionnaire (83.3%) decreased to 74% when more than five questionnaires were completed. Age-related decreases in confidence were significant (p < 0.0001). Women reporting at least one symptom expressed more confidence (41,984/52,379 = 80.2%) than women reporting no symptoms (11,882/18,355 = 64.7%), p < 0.0001. Confidence was unrelated to history of hormone replacement therapy or abnormal ultrasound findings (p = 0.30 and 0.89). The frequency of symptoms relevant to ovarian cancer was much higher than the occurrence of ovarian cancer. Approximately 80.1% of women expressed confidence in what they reported.
Women's Health | 2015
Edward J. Pavlik; R.M. Ore; Aimi Toyama; Dylan Woolum; Thomas E Pavlik; L.A. Baldwin
With the ending of the operational first year of the American Affordable Care Act, health insurance premiums were accessed online. For a US
Southern Medical Journal | 2018
R.M. Ore; Quan Chen; Christopher P. DeSimone; R.W. Miller; L.A. Baldwin; John R. van Nagell; Bin Huang; Thomas C. Tucker; M. Symmes Johnson; Tricia I. Fredericks; Frederick R. Ueland
50,000 income, the lowest premiums ranged from US
Gynecologic Oncology | 2017
Marian S. Johnson; E. Ritter; B.L. Headley; M. Altman; H. Palalay; E. Ueland; L. Haggenjos; E. Harvey; R.M. Ore; T. Fredericks; L.A. Baldwin; Christopher P. DeSimone; R.W. Miller; Frederick R. Ueland; Richard J. Kryscio; J.R. Vannagell; Edward J. Pavlik
805 annually (age 20 years) to US
Gynecologic Oncology | 2017
R.M. Ore; E. Ueland; B.L. Headley; M. Altman; H. Palalay; L. Haggenjos; L.A. Baldwin; R.W. Miller; Christopher P. DeSimone; Marian S. Johnson; T. Fredericks; Frederick R. Ueland; J.R. Vannagell; Edward J. Pavlik
3802 (age 64 years), while the highest ranged from US
Gynecologic Oncology | 2016
S. Lababidi; L.A. Baldwin; J. Lefringhouse; R.M. Ore; Marian S. Johnson; R.W. Miller; Christopher P. DeSimone; Frederick R. Ueland; Edward J. Pavlik; Ann L. Coker
2186 (age 20 years) to US
Gynecologic Oncology | 2016
L.A. Baldwin; M.E. Roberts; J. Lefringhouse; R.M. Ore; Marian S. Johnson; R.W. Miller; Christopher P. DeSimone; Frederick R. Ueland; Edward J. Pavlik; Ann L. Coker
10,326 (age 64 years). The lowest premiums at age 50 years were higher in rural areas in contrast to the highest premiums that were less expensive rurally. At age 64 years, the lowest premiums were 9–12.6% of a US
Gynecologic Oncology | 2016
J. Lefringhouse; Frederick R. Ueland; R.M. Ore; B.L. Headley; E. Lynch; R. Robbins; Marian S. Johnson; L.A. Baldwin; Christopher P. DeSimone; R.W. Miller; J.R. Vannagell; Edward J. Pavlik
50,000 income, while the most expensive varied between 16.5 and 39%. Access to gynecologic oncologists was variable in different networks. Medicaid enrollment nationally was ∼6x higher than paid enrollment. Eligible participation in Affordable Care Act coverage exceeded expectations by >190%. Performance of four healthcare exchange traded funds indicated that investor confidence is high in the American healthcare sector.
Gynecologic Oncology | 2016
J. Lefringhouse; R.M. Ore; Marian S. Johnson; L.A. Baldwin; R.W. Miller; Christopher P. DeSimone; J.R. Vannagell; L. Samoyoa; Dava West; Frederick R. Ueland
Gynecologic Oncology | 2016
Edward J. Pavlik; R.M. Ore; Frederick R. Ueland; J. Lefringhouse; E. Ueland; Marian S. Johnson; L.A. Baldwin; Christopher P. DeSimone; R.W. Miller; Richard J. Kryscio; J.R. Vannagell